Cross-protective HCoV immunity reduces symptom development during SARS-CoV-2 infection

Cross-protective HCoV immunity reduces symptom development during SARS-CoV-2 infection

ABSTRACT Numerous clinical parameters link to severe coronavirus disease 2019, but factors that prevent symptomatic disease remain unknown. We investigated the impact of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) and endemic human coronavirus (HCoV) antibody responses on sympt...

Full description

Bibliographic Details
Main Authors: Irene A. Abela, Magdalena Schwarzmüller, Agne Ulyte, Thomas Radtke, Sarah R. Haile, Priska Ammann, Alessia Raineri, Sonja Rueegg, Selina Epp, Christoph Berger, Jürg Böni, Amapola Manrique, Annette Audigé, Michael Huber, Peter W. Schreiber, Thomas Scheier, Jan Fehr, Jacqueline Weber, Peter Rusert, Huldrych F. Günthard, Roger D. Kouyos, Milo A. Puhan, Susi Kriemler, Alexandra Trkola, Chloé Pasin
Format: Article
Language:English
Published: American Society for Microbiology 2024-02-01
Series:mBio
Subjects:
SARS-CoV-2
pre-exisiting immunity
cross-immunity
respiratory infection
HCoV
children
Online Access:https://journals.asm.org/doi/10.1128/mbio.02722-23

Internet

https://journals.asm.org/doi/10.1128/mbio.02722-23

Similar Items